Key result
RAAS-targeting drugs offer varying degrees of protection on cognition and dementia, representing a potential therapeutic option for Alzheimer's disease that requires further clinical investigation.
Why the study?
Do RAAS-targeting anti-hypertensive drugs improve cognition and protect against dementia in patients with Alzheimer's disease?
Do RAAS-targeting anti-hypertensive drugs improve cognition and protect against dementia in patients with Alzheimer's disease?
RAAS-targeting anti-hypertensive drugs represent a biologically plausible therapeutic option for Alzheimer's disease that requires formal evaluation in randomized clinical trials.
Answers are grounded in this paper and cite their sources.
Should not change practice in Alzheimer's; leaves open whether RAAS-targeting drugs modify cognition in randomized trials.
INTRODUCTION: Hypertension is a modifiable risk factor for Alzheimer's disease (AD) and other dementias. Yet, despite this well-documented association, few of the current strategies to treat AD are directed at this possible target. The renin-aldosterone angiotensin system (RAAS) is a centrally active modifiable pathway that is involved in cerebral blood flow regulation. Currently, three classes of RAAS-targeting drugs are licensed for treatment of peripheral hypertension--angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin II receptor blockers (ARBs) and direct renin inhibitors (DRIs). All of these are generally well tolerated and have been shown to offer varying degrees of protection on aspects of cognition and dementia, thus making them an attractive therapeutic option for AD. AREAS COVERED: This review summarises existing evidence regarding the plausibility of using RAAS-targeting drugs as a strategy to treat AD and highlights unresolved aspects to such approaches, namely the potential impact of altering angiotensin II-mediated processes in the central nervous system. EXPERT OPINION: Continued biochemical research of the RAAS pathway in combination with formal investigation of current RAAS-modifying drugs in randomised clinical trials is now necessary to determine their therapeutic value in AD.
No takes yet. Share an insight, caveat, or question.
Ashby et al. (2013) conducted a review in Alzheimer's disease. RAAS-targeting drugs (ACE-Is, ARBs, DRIs) was evaluated. RAAS-targeting drugs offer varying degrees of protection on cognition and dementia, representing a potential therapeutic option for Alzheimer's disease that requires further clinical investigation.
Synapse has enriched 10 related papers. Consider them for comparative context: